NeuroOne regains Nasdaq minimum bid compliance

NeuroOne Medical Technologies Corporation reports that it has regained compliance with Nasdaq’s minimum bid price requirement.

Rhea-AI Filing Summary

NeuroOne Medical Technologies Corporation reports that it has regained compliance with Nasdaq’s minimum bid price requirement. The company previously received a deficiency letter on May 6, 2025 after its common stock closed below $1.00 per share for 30 consecutive business days.

On April 30, 2026, Nasdaq notified NeuroOne that the closing bid price of its common stock had been at least $1.00 per share for 10 consecutive business days. As a result, Nasdaq considers the company back in compliance with Nasdaq Listing Rule 5550(a)(2), and the bid price matter is closed.

Insights

Equity markets and listing specialist

NeuroOne regains Nasdaq bid-price compliance, resolving a prior delisting risk.

NeuroOne previously fell out of compliance with Nasdaq Listing Rule 5550(a)(2) when its stock traded below $1.00 for 30 consecutive business days. That triggered a formal deficiency process with the Nasdaq Listing Qualifications Staff.

The new notice confirms the closing bid has met or exceeded $1.00 for 10 straight business days as of April 30, 2026, restoring compliance and ending this specific listing issue. This removes an administrative overhang related to potential delisting, although it does not address broader business fundamentals or future share‑price movements.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Minimum bid price threshold: $1.00 per share Non-compliance period trigger: 30 consecutive business days Compliance restoration period: 10 consecutive business days +2 more

5 metrics

Minimum bid price threshold $1.00 per share Nasdaq Listing Rule 5550(a)(2) requirement

Non-compliance period trigger 30 consecutive business days Closing bid below $1.00 preceding May 6, 2025 deficiency letter

Compliance restoration period 10 consecutive business days Closing bid at or above $1.00 before April 30, 2026 notice

Deficiency letter date May 6, 2025 Nasdaq notified NeuroOne of bid price deficiency

Compliance letter date April 30, 2026 Nasdaq confirmed NeuroOne regained bid price compliance

Key Terms

Nasdaq Listing Rule 5550(a)(2), Bid Price Rule, deficiency letter, Nasdaq Capital Market, +1 more

5 terms

Nasdaq Listing Rule 5550(a)(2) regulatory

"the Company did not meet the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2)"

Bid Price Rule regulatory

"the Company did not meet the $1.00 per share minimum bid price requirement... (the “Bid Price Rule”)"

deficiency letter regulatory

"the Company received a deficiency letter (the “Bid Price Notice”) from the Listing Qualifications Department"

Nasdaq Capital Market market

"minimum bid price requirement for continued inclusion on the Nasdaq Capital Market"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

Emerging Growth Company regulatory

"Emerging Growth Company Item 8.01. Other Events"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NeuroOne Medical Technologies (NMTC) announce in this 8-K?

NeuroOne Medical Technologies announced it has regained compliance with Nasdaq’s minimum bid price rule. Nasdaq informed the company that its stock closed at or above $1.00 for 10 straight business days, closing the earlier deficiency matter related to Listing Rule 5550(a)(2).

Why was NeuroOne Medical Technologies (NMTC) previously non-compliant with Nasdaq rules?

NeuroOne was previously non-compliant because its common stock’s closing bid price stayed below $1.00 per share for 30 consecutive business days. This triggered a Nasdaq deficiency letter under Listing Rule 5550(a)(2), which sets the minimum bid price requirement for continued listing on the Nasdaq Capital Market.

How did NeuroOne Medical Technologies (NMTC) regain Nasdaq bid price compliance?

NeuroOne regained compliance after its common stock maintained a closing bid price of at least $1.00 per share for 10 consecutive business days. Nasdaq’s Listing Qualifications Staff confirmed this performance and formally notified the company that it again meets the minimum bid price standard.

What is Nasdaq Listing Rule 5550(a)(2) mentioned for NMTC?

Nasdaq Listing Rule 5550(a)(2) requires a minimum $1.00 per share bid price for companies listed on the Nasdaq Capital Market. NeuroOne temporarily failed this rule, then restored compliance once its stock closed at or above $1.00 for 10 consecutive business days, as confirmed by Nasdaq’s staff.

What does closing the bid price matter mean for NeuroOne Medical Technologies?

Closing the bid price matter means Nasdaq no longer regards NeuroOne as deficient under the minimum bid rule. The company’s common stock remains listed on the Nasdaq Capital Market, and the prior deficiency proceeding tied specifically to Listing Rule 5550(a)(2) has been resolved by Nasdaq staff.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/04/2026 - 08:30 AM EDT Learn about SEC filing dates

false 0001500198 0001500198 2026-04-30 2026-04-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): April 30, 2026

NeuroOne Medical Technologies Corporation

(Exact name of registrant as specified in its charter)

Delaware		001-40439		27-0863354
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

7599 Anagram Dr., Eden Prairie, MN 55344

(Address of principal executive offices and zip code)

952-426-1383

(Registrant’s telephone number including area code)

(Registrant’s former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		NMTC		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events

As previously reported, on May 6, 2025, NeuroOne Medical Technologies Corporation (the “Company”) received a deficiency letter (the “Bid Price Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that because the closing bid price per share of the Company’s common stock was below $1.00 per share for 30 consecutive business days preceding the date of the Bid Price Notice, the Company did not meet the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”).

On April 30, 2026, the Company received a letter from the Staff notifying the Company that it had regained compliance with the Bid Price Rule as a result of the closing bid price of the Company’s common stock being at $1.00 per share or greater for the prior 10 consecutive business days. Accordingly, the letter indicated the Company is in compliance with the Bid Price Rule and the matter is closed.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NEUROONE MEDICAL TECHNOLOGIES CORPORATION
Dated: May 4, 2026
	By:	/s/ David Rosa
		David Rosa
		Chief Executive Officer

2

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB